126 related articles for article (PubMed ID: 1929461)
1. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations.
Rook AH; Prystowsky MB; Cassin M; Boufal M; Lessin SR
Arch Dermatol; 1991 Oct; 127(10):1535-40. PubMed ID: 1929461
[TBL] [Abstract][Full Text] [Related]
2. Sustained remission of Sézary syndrome.
Bouwhuis SA; McEvoy MT; Davis MD
Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
[TBL] [Abstract][Full Text] [Related]
3. [Extracorporeal photopheresis in the therapy of Sézary syndrome].
Marschalkó M; Knobler R; Soós G; Berecz M; Pálóczy K; Rácz I
Orv Hetil; 1993 Jun; 134(23):1253-7. PubMed ID: 8332344
[TBL] [Abstract][Full Text] [Related]
4. The sign of Leser-Trélat in association with Sézary syndrome: simultaneous disappearance of seborrheic keratoses and malignant T-cell clone during combined therapy with photopheresis and interferon alfa.
Cohen JH; Lessin SR; Vowels BR; Benoit B; Witmer WK; Rook AH
Arch Dermatol; 1993 Sep; 129(9):1213-5. PubMed ID: 8395792
[No Abstract] [Full Text] [Related]
5. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
Vonderheid EC; Bigler RD; Greenberg AS; Neukum SJ; Micaily B
Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
[TBL] [Abstract][Full Text] [Related]
6. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
8. A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.
Gardner JM; Introcaso CE; Nasta SD; Kim EJ; Vittorio CC; Rook AH
J Am Acad Dermatol; 2009 Jul; 61(1):112-6. PubMed ID: 19539845
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.
Booken N; Weiss C; Utikal J; Felcht M; Goerdt S; Klemke CD
J Dtsch Dermatol Ges; 2010 Jun; 8(6):428-38. PubMed ID: 20180887
[TBL] [Abstract][Full Text] [Related]
10. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
11. Retinal toxic reactions following photopheresis.
Vagace JM; Gervasini G; Morais F; Benitez J; Alonso N; de Argila D; Arranz I; Bajo R
Arch Dermatol; 2007 May; 143(5):622-5. PubMed ID: 17515512
[TBL] [Abstract][Full Text] [Related]
12. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
Arulogun S; Prince HM; Gambell P; Lade S; Ryan G; Eaton E; McCormack C
J Am Acad Dermatol; 2008 Oct; 59(4):589-95. PubMed ID: 18656282
[TBL] [Abstract][Full Text] [Related]
13. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
14. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of the T-cell clonality in Sezary patients treated by extracorporeal photopheresis using a new assay: the immunoscope technique.
Ingen-Housz-Oro S; Bussel A; Flageul B; Dubertret L; Michel L; Gachelin G; Kourilsky P; Bachelez H; Musette P
Transfus Apher Sci; 2003 Feb; 28(1):35-42. PubMed ID: 12620267
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal photopheresis in Sézary syndrome.
Russell-Jones R; Fraser-Andrews E; Spittle M; Whittaker S
Lancet; 1997 Sep; 350(9081):886. PubMed ID: 9310623
[No Abstract] [Full Text] [Related]
18. Extracorporeal photochemotherapy: indications, methodology, safety aspects, side effects and long-term results.
Heald P; Perez M; McKiernan G; Christiensen I; Edelson R
Photodermatol; 1989 Aug; 6(4):171-6. PubMed ID: 2531380
[No Abstract] [Full Text] [Related]
19. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy.
Osella-Abate S; Zaccagna A; Savoia P; Quaglino P; Salomone B; Bernengo MG
J Am Acad Dermatol; 2001 Jan; 44(1):40-7. PubMed ID: 11148475
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome.
Fritz TM; Kleinhans M; Nestle FO; Burg G; Dummer R
Br J Dermatol; 1999 Jun; 140(6):1144-7. PubMed ID: 10354086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
